Illustration by The Epoch Times, Shutterstock

Millions of Americans take monthly injections to keep migraines at bay. Now researchers say those same drugs may be protecting them from glaucoma, a leading cause of blindness.

A large study, published in Neurology, found that patients taking calcitonin gene-related peptide (CGRP) inhibitors, a newer class of migraine prevention drugs, were 25 percent less likely to develop glaucoma than those on older treatments, raising hope that these medications offer unexpected benefits for eye health.We had a problem loading this article. Please enable javascript or use a different browser. If the issue persists, please visit our help center.